Skip to content
OpenCapital
Get started

Celldex Therapeutics CLDX Increase (Decrease) in Accounts and Other Receivables

Increase (Decrease) in Accounts and Other Receivables at other companies

Eli Lilly logo
Eli LillyLLY
——

Other financials

Income statement

See full
Revenue$15.0K-97.8%
Operating income-$84.4M-34.6%
Net income-$78.7M-46.3%
EPS (diluted)-$1.18-45.7%

Balance sheet

See full
Cash & equivalents$35.7M+109%
Total debt$1.9M-44.3%
Total equity$456.2M-35.1%
Total assets$511.3M-30.9%

Cash flow

See full
Operating cash flow-$65.6M-20.6%
CapEx$1.6M+518%
Free cash flow-$67.2M-23.0%

Valuation

See full
Market cap$2.65B+75.2%
Enterprise value$2.62B+74.4%
P/S3,061.7×+2,862×

Profitability

See full
Operating margin-35,688.5%-39,114pp
Net margin-32,753.6%-35,519pp
FCF margin-26,125.8%-28,907pp

Returns & leverage

See full
Return on equity-48.9%-498pp
Debt / equity0×0.0×
Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's increase (decrease) in accounts and other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celldex Therapeutics's increase (decrease) in accounts and other receivables?
Celldex Therapeutics (CLDX) reported increase (decrease) in accounts and other receivables of -$1.79M in Q1 2026.
How has Celldex Therapeutics's increase (decrease) in accounts and other receivables changed year-over-year?
Celldex Therapeutics's increase (decrease) in accounts and other receivables decreased by 590.4% year-over-year, from $364K to -$1.79M.
What is the long-term trend for Celldex Therapeutics's increase (decrease) in accounts and other receivables?
Over 4 years (2021 to 2025), Celldex Therapeutics's increase (decrease) in accounts and other receivables has grown at a -4.4% compound annual growth rate (CAGR), from -$1.57M to $1.32M.